Seminars in Fetal & Neonatal Medicine
Volume 13, Issue 2 , Pages 63-68 , April 2008

Non-invasive prenatal diagnosis and determination of fetal Rh status

  • C. Ellen van der Schoot

      Affiliations

    • Sanquin Research, Amsterdam, and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Plesmanlaan 125, 1066 CX Amsterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 205123377; fax: +31 205123474.
    • ,
  • Sinuhe Hahn

      Affiliations

    • University Women's Hospital/Department of Research, University Hospital Basel, Switzerland
    • ,
  • Lyn S. Chitty

      Affiliations

    • Clinical and Molecular Genetics Unit, Institute of Child Health and Fetal Medicine Unit, University College London Hospitals NHS Foundation Trust, London, UK

References 

  1. Daniels G. Human blood groups. 2nd ed.. Oxford: Blackwell Science; 2002;
  2. Colin Y, Chérif-Zahar B, Le Van Kim C, Raynal V, Van Huffel V, Cartron J-P. Genetic basis of the RhD-positive and RhD-negative blood group polymorphism as determined by Southern analysis. Blood. 1991;78:2747–2752
  3. Walker W, Murray S, Russell JK. Stillbirth due to hemolytic disease of the newborn. J Obstet Gynaecol Br Emp. 1957;44:573–581
  4. Kumpel BM. Monoclonal anti-D development programme. Transpl Immunol. 2002;10:199–204
  5. National Institute for Clinical Excellence . Technology appraisal guidance 41. Guidance on the use of routine antenatal anti-D prophylaxis for D-negative women. London: NICE; 2002;
  6. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med. 1999;340:1228–1233
  7. Lo YMD, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CWG. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997;350:485–487
  8. Lo YM, Hjelm NM, Fidler C, et al. Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. N Engl J Med. 1998;339:1734–1738
  9. Faas BH, Beuling EA, Christiaens GC, von dem Borne AE, van der Schoot CE. Detection of fetal RhD-specific sequences in maternal plasma. Lancet. 1998;352:1196
  10. Finning KM, Martin PG, Soothill PW, Avent ND. Prediction of fetal D status from maternal plasma: introduction of a new noninvasive fetal RHD genotyping service. Transfusion. 2002;42:1079–1085
  11. Singleton BK, Green CA, Avent ND, et al. The presence of an RHD pseudogene containing a 37 base pair duplication and a nonsense mutation in most Africans with the Rh D-negative blood group phenotype. Blood. 2000;95:12–18
  12. Faas BH, Beckers EA, Wildoer P, et al. Molecular background of VS and weak C expression in blacks. Transfusion. 1997;37:38–44
  13. Grootkerk-Tax MG, Soussan AA, de Haas M, Maaskant-van Wijk PA, van der Schoot CE. Evaluation of prenatal RHD typing strategies on cell-free fetal DNA from maternal plasma. Transfusion. 2006;46:2142–2148
  14. Beckers EA, Faas BH, Simsek S, et al. The genetic basis of a new partial D antigen: DDBT. Br J Haematol. 1996;93:720–727
  15. Flegel WA, Denomme GA, Yazer MH. On the complexity of d antigen typing: a handy decision tree in the age of molecular blood group diagnostics. J Obstet Gynaecol Can. 2007;29:746–752
  16. Costa JM, Giovangrandi Y, Ernault P, et al. Foetal RHD genotyping in maternal serum during the first trimester of pregnancy. Br J Haematol. 2002;119:255–260
  17. van der Schoot CE, Ait Soussan A, Dee R, Bonsel GJ, de Haas M. Screening for foetal RhD-genotype by plasma PCR in all D-negative pregnant women is feasible. Vox Sang. 2004;87(suppl):9
  18. Finning K, Martin P, Daniels G. A clinical service in the UK to predict fetal Rh (Rh) D blood group using free fetal DNA in maternal plasma. Ann N Y Acad Sci. 2004;1022:119–123
  19. Rouillac-Le Sciellour C, Puillandre P, Gillot R, et al. Large-scale pre-diagnosis study of fetal RHD genotyping by PCR on plasma DNA from D-negative pregnant women. Mol Diagn. 2004;8:23–31
  20. Gautier E, Benachi A, Giovangrandi Y, et al. Fetal RhD genotyping by maternal serum analysis: a two-year experience. Am J Obstet Gynecol. 2005;192:666–669
  21. Finning K, Martin P, Summers J, Massey E, Poole G, Daniels G. Screening for fetal RHD in D negative pregnant women will obviate unnecessary treatment with anti-RhD immunoglobulin. Br Med J, in press.
  22. Daniels G, Finning K, Martin P, Summers J. Fetal blood group genotyping. Present and future. Ann N Y Acad Sci. 2006;1075:88–95
  23. Page-Christiaens GC, Bossers B, van der Schoot CE, De Haas M. Use of bi-allelic insertion/deletion polymorphisms as a positive control for fetal genotyping in maternal blood: first clinical experience. Ann N Y Acad Sci. 2006;1075:123–129
  24. Chan KC, Ding C, Gerovassili A, et al. Hypermethylated RASSF1A in maternal plasma: a universal fetal DNA marker that improves the reliability of noninvasive prenatal diagnosis. Clin Chem. 2006;52:2211–2218
  25. Joint UKBTS/NIBSC professional advisory committee position statement 01. http://www.transfusionguidelines.org.uk/index.asp?Publication = DL&Section = 12&pageid = 794 [accessed 15/5/07].
  26. Lo YM, Tein MS, Lau TK, et al. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for non-invasive prenatal diagnosis. Am J Hum Genet. 1998;62:768–775
  27. Legler TJ, Liu Z, Mavrou A, et al. Workshop report on the extraction of foetal DNA from maternal plasma. Prenat Diagn. 2007;27(9):824–829
  28. Clausen FB, Krog GR, Rieneck K, Dziegiel MH. Improvement in fetal DNA extraction from maternal plasma. Evaluation of the nucliSens magnetic extraction system and the QIAamp DSP virus kit in comparison with the QIAamp DNA blood mini kit. Prenat Diagn. 2007;27:6–10
  29. Koelewijn JM, Vrijkotte TGM, van der Schoot CE, de Haas M. Effect of screening for red cell antibodies, other than anti-RhD, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands. Transfusion, in press
  30. Ghevaert C, Campbell K, Walton J, et al. Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia. Transfusion. 2007;47:901–910
  31. Hromadnikova I, Vesela K, Benesova B, et al. Non-invasive fetal RHD and RHCE genotyping from maternal plasma in alloimmunized pregnancies. Prenat Diagn. 2005;25:1079–1083
  32. Legler TJ, Lynen R, Maas JH, et al. Prediction of fetal Rh D and Rh CcEe phenotype from maternal plasma with real-time polymerase chain reaction. Transfus Apheresis Sci. 2002;27:217–223
  33. Finning K, Martin P, Summers J, Daniels G. Fetal genotyping for the K (Kell) and Rh C, c, and E blood groups on cell-free fetal DNA in maternal plasma. Transfusion. 2007;47:2126–2133
  34. Li Y, Finning K, Daniels G, Hahn S, Zhong Z, Holzgreve W. Non-invasive genotyping fetal Kell blood group (KEL1) using cell-free fetal DNA in maternal plasma by MALDI-TOF mass spectrometry. Prenat Diagn, submitted for publication.
  35. Bianchi DW, Avent ND, Costa JM, van der Schoot CE. Noninvasive prenatal diagnosis of fetal Rhesus D: ready for Prime(r) Time. Obstet Gynecol. 2005;106:841–844

PII: S1744-165X(07)00158-8

doi: 10.1016/j.siny.2007.12.012

Seminars in Fetal & Neonatal Medicine
Volume 13, Issue 2 , Pages 63-68 , April 2008

Article Tools

* Image Usage & Resolution